Clinical Trials Logo

Chronic Kidney Diseases clinical trials

View clinical trials related to Chronic Kidney Diseases.

Filter by:

NCT ID: NCT03416192 Withdrawn - Clinical trials for Chronic Kidney Diseases

12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.

Start date: February 2019
Phase: N/A
Study type: Interventional

The medium cut-off dialysis (MCO) membrane has been developed to improve middle molecule removal compared to standard high-flux dialysis filters. The aim of this study is to compare levels of middle molecules after 12 weeks of MCO hemodialysis, compared to 12 weeks of hemodiafiltration using standard high-flux filter.

NCT ID: NCT03397550 Withdrawn - Clinical trials for Chronic Kidney Diseases

The Relationship Between Salt Restriction and Taste Sensitivity in Patients With Chronic Kidney Disease

Start date: June 18, 2022
Phase:
Study type: Observational

The compliance of salt restriction in patients with CKD may be associated with taste sensitivity.

NCT ID: NCT03073369 Withdrawn - Anemia Clinical Trials

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

The purpose of the study is to learn more about how treatment with vitamin D can affect iron metabolism and blood levels of hepcidin (hormone controlling iron levels) in people with chronic kidney disease (CKD). Iron is an essential mineral which is a major component of proteins that carry oxygen in the blood. Problems with iron metabolism can lead to low blood levels (anemia), which can commonly happen in people with CKD. New research over the last decade has uncovered a new hormone called `hepcidin', which is made in the liver and released into the blood. Hepcidin controls how much iron is in the blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found to be high in people with CKD, and a recent small study in people with normal kidney function showed that treatment with vitamin D decreased hepcidin levels. In this study, investigators would like to examine the effects of vitamin D (Ergocalciferol) on iron metabolism and blood levels of hepcidin in individuals with CKD.

NCT ID: NCT03062176 Withdrawn - Clinical trials for Chronic Kidney Diseases

Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease

E-HART
Start date: April 3, 2017
Phase: Phase 2
Study type: Interventional

Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with advanced chronic kidney disease and heart failure.